v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting

9. Segment Reporting

The Company has one reportable segment, which is related to the research and development of its product candidates focused on complement-mediated diseases of the body, brain and eye for which there is significant unmet medical need. The accounting policies of the one reportable segment are the same as those described in the summary of significant accounting policies. See Note 2—Basis of Presentation and Significant Accounting Policies.

The segment is managed on a consolidated basis and the chief operating decision maker, or CODM, uses total operating expenses and consolidated net loss to assess performance, forecast future financial results and allocate resources. In assessing the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. This includes a review of budget versus actual expenses and direct program spend, which includes clinical costs, consultant fees, manufacturing expenses, and other direct external costs.

The following table presents the operations for the reportable segment for the three and six months ended June 30, 2026 and 2025 (in thousands):

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and development - external expenses(1)

 

$

34,847

 

 

$

31,278

 

 

$

58,668

 

 

$

65,776

 

Research and development - personnel

 

 

6,952

 

 

 

8,376

 

 

 

14,362

 

 

 

17,422

 

General and administrative - personnel

 

 

2,686

 

 

 

2,153

 

 

 

5,603

 

 

 

4,493

 

Other general and administrative expenses(2)

 

 

7,389

 

 

 

5,174

 

 

 

14,599

 

 

 

11,080

 

Depreciation expense

 

 

540

 

 

 

540

 

 

 

1,079

 

 

 

1,077

 

Stock-based compensation

 

 

4,813

 

 

 

4,205

 

 

 

8,969

 

 

 

9,283

 

Total operating expense

 

 

57,227

 

 

 

51,726

 

 

 

103,280

 

 

 

109,131

 

Loss from operations

 

 

(57,227

)

 

 

(51,726

)

 

 

(103,280

)

 

 

(109,131

)

Interest and other income, net

 

 

1,879

 

 

 

2,570

 

 

 

3,790

 

 

 

5,619

 

Consolidated segment net loss

 

$

(55,348

)

 

$

(49,156

)

 

$

(99,490

)

 

$

(103,512

)

 

__________________

(1) Research and development - external expenses include program expenses, other non-program specific expenses and other research expenses.

(2) Other general and administrative expenses include consulting and professional services fees for business development, legal, accounting, tax, and facilities costs.